Aberrant splicing events in CD34⁺cells of patients with SFmut MDS. (A-C) Venn diagrams showing the aberrant splicing events identified in SF3B1 (A), SRSF2 (B), and U2AF1 (C) mutant MDS cases vs healthy control individuals and patients with SFwt MDS. (D-F) Doughnut charts showing the distribution of the aberrant splicing events identified in SF3B1 (D), SRSF2 (E), and U2AF1 (F) mutant MDS cases by event type. For each category, the number of significant aberrant splicing events was normalized to the total number of events identified by the rMATS pipeline. (G-I) Hierarchical clustering of SF3B1 (G), SRSF2 (H), and U2AF1 (I) mutant MDS samples, with wild-type MDS and healthy control samples using the rMATS-calculated inclusion levels of the 245, 236, and 287 aberrant splicing events identified.